Egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib

Keigo Kobayashi, Katsuhiko Naoki, Aoi Kuroda, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Tomoko Betsuyaku

Research output: Contribution to journalArticle

Abstract

A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple che-motherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.

Original languageEnglish
Pages (from-to)1007-1010
Number of pages4
JournalInternal Medicine
Volume57
Issue number7
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Non-Small Cell Lung Carcinoma
Lung
Epidermal Growth Factor Receptor
Tomography
Interstitial Lung Diseases
Protein-Tyrosine Kinases
Glass
Lung Neoplasms
Thorax
Biopsy
Recurrence
Drug Therapy
Mutation
osimertinib
Therapeutics

Keywords

  • Drug-induced pneumonitis
  • EGFR-T790M
  • Non-small cell lung cancer
  • Osimertinib
  • Stop-and-go
  • Transient asymptomatic pulmonary opacities

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib. / Kobayashi, Keigo; Naoki, Katsuhiko; Kuroda, Aoi; Yasuda, Hiroyuki; Kawada, Ichiro; Soejima, Kenzo; Betsuyaku, Tomoko.

In: Internal Medicine, Vol. 57, No. 7, 01.01.2018, p. 1007-1010.

Research output: Contribution to journalArticle

@article{ae3333be21f44b3ea15f7d177213c106,
title = "Egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib",
abstract = "A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple che-motherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.",
keywords = "Drug-induced pneumonitis, EGFR-T790M, Non-small cell lung cancer, Osimertinib, Stop-and-go, Transient asymptomatic pulmonary opacities",
author = "Keigo Kobayashi and Katsuhiko Naoki and Aoi Kuroda and Hiroyuki Yasuda and Ichiro Kawada and Kenzo Soejima and Tomoko Betsuyaku",
year = "2018",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.9609-17",
language = "English",
volume = "57",
pages = "1007--1010",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "7",

}

TY - JOUR

T1 - Egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib

AU - Kobayashi, Keigo

AU - Naoki, Katsuhiko

AU - Kuroda, Aoi

AU - Yasuda, Hiroyuki

AU - Kawada, Ichiro

AU - Soejima, Kenzo

AU - Betsuyaku, Tomoko

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple che-motherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.

AB - A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple che-motherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.

KW - Drug-induced pneumonitis

KW - EGFR-T790M

KW - Non-small cell lung cancer

KW - Osimertinib

KW - Stop-and-go

KW - Transient asymptomatic pulmonary opacities

UR - http://www.scopus.com/inward/record.url?scp=85044742665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044742665&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.9609-17

DO - 10.2169/internalmedicine.9609-17

M3 - Article

VL - 57

SP - 1007

EP - 1010

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 7

ER -